Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors

Nature Reviews Drug Discovery

Volumn 4, Issue 5, 2005, Pages 421-440

  Jagtap, Prakash ^a   Szabo, Csaba ^a,b  

^a INOTEK CORPORATION   (United States)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

1,11B DIHYDRO [2H]BENZOPYRANO[4,3,2 DE]ISOQUINOLIN 3 ONE; 1,5 DIHYDROXYISOQUINOLINE; 2 METHYL 3,5,7,8 TETRAHYDROTHIPYRANO[4,3 D]PYRIMIDINE 4 ONE; 3 AMINOBENZAMIDE; 3,4 DIHYDRO 5 [4 1(1 PIPERIDINYL)BUTOXY] 1(2H) ISOQUINOLINONE; 3,4 DIHYDRO 5 METHYLISOQUINOLINONE; 3,4 DIHYDROISOQUINOLIN 1(2H) ONE; 4 HYDROXYQUINAZOLINE; 5 AMINOISOQUINOLINONE; 5 IODO 6 AMINO 1,2 BENZOPYRONE; 6(5H) PHENANTHRIDINONE; ACTIVATING TRANSCRIPTION FACTOR 2; AG 140361; AG 140699; ANGIOTENSIN; ANTINEOPLASTIC AGENT; APOPTOSIS INDUCING FACTOR; AZA 5[H] PHENANTHRIDIN 6 ONE; BENZAMIDE; CAMPTOTHECIN; CEP 6800; CERAMIDE; CISPLATIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYTOKINE; DEXAMETHASONE; DNA; DOXORUBICIN; DR 2313; EB 47; ENZYME INHIBITOR; ETOPOSIDE; FAS ANTIGEN; FR 257517; GPI 6150; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INO 1001; INTERCELLULAR ADHESION MOLECULE 1; IRINOTECAN; ISOINDOLINONE DERIVATIVE; ISOPROTEIN; ISOQUINOLIN 1(2H) ONE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NICOTINAMIDE DERIVATIVE; ONO 1924H; PARACETAMOL; PD 128763; PHTHALAZIN 1(2H) ONE; QUINAZOLIN 4(3H) ONE; STAT1 PROTEIN; TEMOZOLOMIDE; TOPOTECAN; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

APOPTOSIS; BRAIN DISEASE; CARDIOTOXICITY; CELL DEATH; CELL ENERGY; CELL FUNCTION; CENTRAL NERVOUS SYSTEM TUMOR; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLITIS; CYTOTOXICITY; DIABETES MELLITUS; DNA DAMAGE; DNA REPAIR; DOWN REGULATION; DRUG BINDING SITE; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; EAR DISEASE; ENZYME ACTIVATION; EYE DISEASE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HEART DISEASE; HEART INFARCTION; HUMAN; INFLAMMATORY DISEASE; LIVER TOXICITY; LUNG DISEASE; MELANOMA; NONHUMAN; PARENCHYMA; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FAMILY; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SHOCK; SIGNAL TRANSDUCTION; SKIN DISEASE; STRUCTURE ANALYSIS; VASCULAR DISEASE;

ANIMALS; ENZYME INHIBITORS; HUMANS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 18944390248     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1718     Document Type: Review

References (170)

1. Chambon, P., Weil, J. D. & Mandel, P. NAD activation of a new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem. Biophys. Res. Comm. 11, 39-45 (1963).
2. Ame, J. C., Spenlehauer, C. & de Murcia, G. The PARP superfamily. Bioessays 26, 882-893 (2004).
3. Nguewa, P. A., Fuertes, M. A., Valladares, B., Alonso, C. & Perez, J. M. Poly(ADP-ribose) polymerases: homology, structural domains and functions. Novel therapeutical applications. Prog. Biophys. Mol. Biol. 88, 143-172 (2005).
4. Virág, L. & Szabó, C. The therapeutic potential of poly (ADP-ribose) polymerase inhibitors. Pharmacol. Rev. 54, 375-429 (2002).
5. Davidovic, L., Vodenicharov, M., Affar, E. B. & Poirier, G. G. Importance of poly(ADP-ribose) glycohydrolase in the control of poly(ADP-ribose) metabolism. Exp. Cell Res. 268, 7-13 (2001).
6. Pillai, J. B., Russell, H. M., Raman, J. S., Jeevanandam, V. & Gupta, M. P. Increased expression of poly (ADP) ribose polymerase-1 contributes to caspase-independent myocyte cell death during heart failure. Am. J. Physiol. Heart Circ. Physiol. 288, H486-H496 (2005).
7. Bauer, P. I. et al. Inhibition of DNA binding by the phosphorylation of poly ADP-ribose polymerase protein catalysed by protein kinase C. Biochem, Biophys. Res. Commun. 187, 730-736 (1992).
8. Homburg, S. et al. A fast signal-induced activation of poly(ADP-ribose) polymerase: a novel downstream target of phospholipase C. J. Cell Biol. 150, 293-307 (2000).
9. Sastry, S. S. & Kun, E. The interaction of adenosine diphosphoribosyl transferase (ADPRT) with a cruciform DNA. Biochem. Biophys. Res. Commun. 167, 842-847 (1990).
10. Wallace, D. C. A mitochondrial paradigm for degenerative diseases and ageing. Novartis Found Symp. 235, 247-263 (2001).
11. Bouchard, V. J., Rouleau, M. & Poirier, G. G. PARP-1, a determinant of cell survival in response to DNA damage. Exp. Hematol. 31, 446-454 (2003).
12. Huber, A., Bai, P., de Murcia, J. M. & de Murcia, G. PARP-1, RARP-2 and ATM in the DNA damage response: functional synergy in mouse development. DNA Repair (Amst.) 3, 1103-1108 (2004).
13. de Murcia, J. M. et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc. Natl Acad. Sci. USA 94, 7303-7307 (1997).
14. Dantzer, F. et al. Base excision repair is impaired in mammalian cells lacking poly(ADP-ribose) polymerase-1. Biochemistry 39, 7559-7569 (2000).
15. Flohr, C., Burkle, A., Radicella, J. P. & Epe, B. Poly(ADP-ribosyl)ation accelerates DNA repair in a pathway dependent on Cockayne syndrome B protein. Nucleic Acids Res. 31, 5332-5337 (2003).
16. von Kobbe, C. et al. Poly(ADP-ribose) polymerase 1 regulates both the exonuclease and helicase activities of the Werner syndrome protein. Nucleic Acids Res. 32, 4003-4014 (2004).
17. Kun, E. & Bauer, P. I. Cell biological functions of PARP I: an overview. Ital. J. Biochem. 50, 15-18 (2001).
18. Yung, T. M., Sato, S. & Satoh, M. S. Poly(ADP-ribosyl)ation as a DNA damage-induced post-translational modification regulating poly(ADP-ribose) polymerase-1-topoisomerase I interaction. J. Biol. Chem. 279, 39686-39696 (2004).
19. Oei, S. L. & Ziegler, M. ATP for the DNA ligation step in base excision repair is generated from poly(ADP-ribose). J. Biol. Chem. 275, 23234-23239 (2000).
20. Vodenicharov, M. D., Sallmann, F. R., Satoh, M. S. & Poirier, G. G. Base excision repair is efficient in cells lacking poly(ADP-ribose) polymerase 1. Nucleic Acids Res. 28, 3887-3896 (2000).
21. Russell, J., Sanderson, R. J. & Lindahl, T. Down-regulation of DNA repair synthesis at DNA single-strand interruptions in poly(ADP-ribose) polymerase-1 deficient murine cell extracts. DNA Repair 1, 547-558 (2002).
22. Allinson, S. L., Dianova, I. I. & Dianov, G. L. Poly(ADP-ribose) polymerase in base excision repair: always engaged, but not essential for DNA damage processing. Acta Biochim. Pol. 50, 169-179 (2003).
23. Tong, W. M. et al. Null mutation of DNA strand break-binding molecule poly(ADP-ribose) polymerase causes medulloblastomas in p53(-/-) mice. Am. J. Pathol. 162, 343-352 (2003).
24. Nozaki, T. et al. PARP-1 deficiency implicated in colon and liver tumorigenesis induced by azoxymethane. Cancer Sci. 94, 497-500 (2003).
25. Masutani, M., Nakagama, H. & Sugimura, T. Poly(ADP-ribose) and carcinogenesis. Genes Chromosom. Cancer 38, 339-348 (2003).
26. Conde, C. et al. Loss of poly(ADP-ribose) polymerase-1 causes increased tumour latency in p53-deficient mice. EMBO J. 20, 3535-3543 (2001).
27. Hans, M. A., Muller, M., Meyer-Ficca, M., Burkle, A. & Kupper, J. H. Overexpression of dominant negative PARP interferes with tumor formation of HeLa cells in nude mice: evidence for increased tumor cell apoptosis in vivo. Oncogene 18, 7010-7015 (1999).
28. Martin-Oliva, D. et al. Crosstalk between PARP-1 and NF-κB modulates the promotion of skin neoplasia. Oncogene 23, 5275-5283 (2004).
29. Simbulan-Rosenthal, C. M. et al. Misregulation of gene expression in primary fibroblasts lacking poly(ADP-ribose) polymerase. Proc. Natl Acad. Sci. USA 97, 11274-11279 (2000).
30. Simbulan-Rosenthal, C. M. et al. Inhibition of poly(ADP-ribose) polymerase activity is insufficient to induce tetraploidy. Nucleic Acids Res. 29, 841-849 (2001).
31. Kraus, W. L. & Lis, J. T. PARP goes transcription. Cell 113, 677-683 (2003).
32. Reale, A., Matteis, G. D., Galleazzi, G., Zampieri, M. & Caiafa, P. Modulation of DNMT1 activity by ADP-ribose polymers. Oncogene 24, 13-19 (2005).
33. Hassa, P. O. & Hottiger, M. O. The functional role of poly(ADP-ribose)polymerase 1 as novel coactivator of NF-κB in inflammatory disorders. Cell. Mol. Life Sci. 59, 1534-1553 (2002).
34. Hassa, P. O., Buerki, C., Lombardi, C., Imhof, R. & Hottiger, M. O. Transcriptional coactivation of nuclear factor-κB-dependent gene expression by p300 is regulated by poly(ADP)-ribose polymerase-1. J. Biol. Chem. 278, 45145-45153 (2003).
35. Nakajima, H. et al. Critical role of the automodification of poly(ADP-ribose) polymerase-1 in nuclear factor-κB-dependent gene expression in primary cultured mouse glial cells. J. Biol. Chem. 279, 42774-42786 (2004).
36. Hasko, G. et al. Poly(ADP-ribose) polymerase is a regulator of chemokine production: relevance for the pathogenesis of shock and inflammation. Mol. Med. 8, 283-289 (2002).
37. Garcia-Soriano, F. et al. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nature Med. 7, 108-113 (2001).
38. Du, X. et al. Inhibition of GAPDH actvity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J. Clin. Invest. 112, 1049-1057 (2003).
39. Carrillo, A. et al. Transcription regulation of TNF-α-early response genes by poly(ADP-ribose) polymerase-1 in murine heart endothelial cells. Nucleic Acids Res. 32, 757-766 (2004).
40. Ota, K., Kameoka, M., Tanaka, Y., Itaya, A. & Yoshihara, K. Expression of histone acetyltransferases was down-regulated in poly(ADP-ribose) polymerase-1-deficient murine cells. Biochem. Biophys. Res. Commun. 310, 312-317 (2003).
41. Zingarelli, B. et al. Absence of poly(ADP-ribose)polymerase-1 alters nuclear factor-κB activation and gene expression of apoptosis regulators after reperfusion injury. Mol. Med. 9, 143-153 (2003).
42. Zingarelli, B., O'Connor, M. & Hake, P. W. Inhibitors of poly (ADP-ribose) polymerase modulate signal transduction pathways in colitis. Eur. J. Pharmacol. 469, 183-194 (2003).
43. Veres, B. et al. Decrease of the inflammatory response and induction of the Akt/protein kinase B pathway by poly-(ADP-ribose) polymerase 1 inhibitor in endotoxin-induced septic shock. Biochem. Pharmacol. 65, 1373-1382 (2003).
44. Veres, B. et al. Regulation of kinase cascades and transcription factors by a poly(ADP-ribose) polymerase-1 inhibitor, 4-hydroxyquinazoline, in lipopolysaccharide-induced inflammation in mice. J. Pharmacol. Exp. Ther. 310, 247-255 (2004).
45. Szabó, C. et al. Regulation of components of the inflammatory response by 5-iodo-6-amino-1,2-benzopyrone, and inhibitor of poly (ADP-ribose) synthetase and pleiotropic modifier of cellular signal pathways. Int. J. Oncol. 10, 1093-1101 (1997).
46. Ha, H. C. Defective transcription factor activation for proinflammatory gene expression in poly(ADP-ribose) polymerase 1-deficient glia. Proc. Natl Acad. Sci. USA 101, 5087-5092 (2004).
47. Simbulan-Rosenthal, C. M. et al. Misregulation of gene expression in primary fibroblasts lacking poly(ADP-ribose) polymerase. Proc. Natl Acad. Sci. USA 97, 11274-11279 (2000).
48. Ha, H. C., Hester, L. D. & Snyder, S. H. Poly(ADP-ribose) polymerase-1 dependence of stress-induced transcription factors and associated gene expression in glia. Proc. Natl Acad. Sci. USA 99, 3270-3275 (2002).
49. Zingarelli, B. et al. Differential regulation of activator protein-1 and heat shock factor-1 in myocardial ischemia and reperfusion injury: role of poly(ADP-ribose) polymerase-1. Am. J. Physiol. Heart Circ. Physiol. 286, H1408-H1415 (2004).
50. Ivana-Scovassi, A. & Diederich, M. Modulation of poly(ADP-ribosylation) in apoptotic cells. Biochem. Pharmacol. 68, 1041-1047 (2004).
51. Kwan, J. A. et al. Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro. FASEB J. 18, 690-692 (2004).
52. Leist, M. et al. Apoptosis in the absence of poly-(ADP-ribose) polymerase. Biochem. Biophys. Res. Commun. 233, 518-522 (1997).
53. Virág, L. et al. Peroxynitrite-induced thymocyte apoptosis: the role of caspases and poly (ADP-ribose) synthetase activation. Immunology 94, 345-355 (1998).
54. Herceg, Z. & Wang, Z. Q. Failure of poly(ADP-ribose) polymerase cleavage by caspases leads to induction of necrosis and enhanced apoptosis. Mol. Cell. Biol. 19, 5124-5133 (1999).
55. Aikin, R., Rosenberg, L., Paraskevas, S. & Maysinger, D. Inhibition of caspase-mediated PARP-1 cleavage results in increased necrosis in isolated islets of Langerhans. J. Mol. Med. 82, 389-397 (2004).
56. Eliasson, M. J. et al. Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nature Med. 3, 1089-1095 (1997).
57. Zingarelli, B., Salzman, A. L. & Szabó, C. Genetic disruption of poly (ADP-ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia/reperfusion injury. Circ. Res. 83, 85-94 (1998).
58. Zhang, J., Dawson, V. L., Dawson, T. M. & Snyder, S. H. Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity. Science 263, 687-689 (1994).
59. Heller, B. et al. Inactivation of the poly(ADP-ribose) polymerase gene affects oxygen radical and nitric oxide toxicity in islet cells. J. Biol. Chem. 270, 11176-11180 (1995).
60. Virág, L., Salzman, A. L. & Szabó, C. Poly(ADP-ribose) synthetase activation mediates mitochondrial injury during oxidant-induced cell death. J. Immunol. 161, 3753-3759 (1998).
61. Ha, H. C. & Snyder, S. H. Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc. Natl Acad. Sci. USA 96, 13978-13982 (1999).
62. Szabó, C., Zingarelli, B., O'Connor, M. & Salzman, A. L. DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. Proc. Natl Acad. Sci. USA 93, 1753-1758 (1996).
63. Zingarelli, B., O'Connor, M., Wong, H., Salzman, A. L. & Szabó, C. Peroxynitrite-mediated DNA strand breakage activates poly-adenosine diphosphate ribosyl synthetase and causes cellular energy depletion in macrophages stimulated with bacterial lipopolysaacharide. J. Immunol. 156, 350-358 (1996).
64. Berger, N. A. & Berger, S. J. Metabolic consequences of DNA damage: the role of poly (ADP-ribose) polymerase as mediator of the suicide response. Basic Life Sci. 38, 357-363 (1986).
65. Berger, N. A., Whitacre, C. M., Hashimoto, H., Berger, S. J. & Chatterjee, S. NAD and poly(ADP-ribose) regulation of proteins involved in response to cellular stress and DNA damage. Biochimie 77, 364-367 (1995).
66. Skaper, S.D. et al. Poly(ADP-ribose) polymerase-1 in acute neuronal death and inflammation: a strategy for neuroprotection. Ann. NY Acad. Sci. 993, 217-228 (2003).
67. Szabó, G., Liaudet, L., Hagl, S. & Szabó, C. Poly(ADP-ribose) polymerase activation in the reperfused myocardium. Cardiovasc. Res. 61, 471-480 (2004).
68. Ying, W., Alano, C. C., Garnier, P. & Swanson, R. A. NAD(+) as a metabolic link between DNA damage and cell death. J. Neurosci. Res. 79, 216-223 (2005).
69. Chiarugi, A. Poly(ADP-ribose) polymerase: killer or conspirator? The 'suicide hypothesis' revisited. Trends Pharmacol. Sci. 23, 122-129 (2002).
70. Ying, W., Garnier, P. & Swanson, R. A. NAD+ repletion prevents PARP-1-induced glycolytic blockade and cell death in cultured mouse astrocytes. Biochem. Biophys. Res. Commun. 308, 809-813 (2003).
71. Ying, W., Chen, Y., Alano, C. C. & Swanson, R. A. Tricarboxylic acid cycle substrates prevent PARP-madiated death of neurons and astrocytes. J. Cereb. Blood Flow Metab. 22, 774-779 (2002).
72. Wang, H. et al. Apoptosis-inducing factor substitutes for caspase executioners in NMDA-triggered excitotoxic neuronal death. J. Neurosci. 24, 10963-10973 (2004).
73. Xiao, C. Y., Chen, M., Zsengeller, Z. & Szabó, C. Poly(ADP-ribose) polymerase contributes to the development of myocardial infarction in diabetic rats and regulates the nuclear translocation of apoptosis-inducing factor. J. Pharmacol. Exp. Ther. 310, 498-504 (2004).
74. Hong, S. J., Dawson, T. M. & Dawson, V. L. Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends Pharmacol. Sci. 25, 259-264 (2004).
75. + depletion and cell death induced by oxidative stress. J. Biol. Chem. 278, 18426-18433 (2003).
76. Lai, Y. C. et al. Poly-ADP-ribosylation as a post-translational modification of mitochondrial proteins: 82. Crit. Care Med. 32, A21 (2004).
77. Scovassi, A. I. Mitochondrial poly(ADP-ribosylation): from old data to new perspectives. FASEB J. 18, 1487-1488 (2004).
78. Szabó, C. & Dawson, V. L. Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion. Trends Pharmacol. Sci. 19, 287-298 (1998).
79. Liaudet, L. et al. Protection against hemorrhagic shock in mice genetically deficient in poly(ADP-ribose)polymerase. Proc. Natl Acad. Sci. USA 97, 10203-10208 (2000).
80. Casey, P. J. et al. PARP inhibition modulates spinal cord dysfunction after thoracoabdominal aortic ischemia-reperfusion. J. Vasc. Surg. 41, 99-107 (2005).
81. Kendirci, M. et al. PARP inhibition restores in vivo erectile function in bilateral cavernous nerve injured rats. J. Sex. Med. (Suppl. 1), 107 (2004).
82. Khan, A. U. et al. Liposomal NAD(+) prevents diminished O(2) consumption by immunostimulated Caco-2 cells. Am. J. Physiol. Lung Cell Mol. Physiol. 282, L1082-L1091 (2002).
83. Soriano, F. G , Pacher, P., Mabley, J., Liaudet, L. & Szabó, C. Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase. Circ. Res. 89, 684-691 (2001).
84. Jijon, H. B. et al. Inhibition of poly(ADP-ribose) polymerase attenuates inflammation in a model of chronic colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 279, G641-G651 (2000).
85. Suarez-Pinzon, W. L., Mabley, J. G., Power, R., Szabó, C. & Rabinovitch, A. Poly (ADP-ribose) polymerase inhibition prevents spontaneous and recurrent autoimmune diabetes in NOD mice by inducing apoptosis of islet-infiltrating leukocytes. Diabetes 52, 1683-1688 (2003).
86. Endres, M. et al. Role of peroxynitrite and neuronal nitric oxide synthase in the activation of poly(ADP-ribose) synthetase in a murine model of cerebral ischemia-reperfusion. Neurosci. Lett. 248, 41-44 (1998).
87. Liaudet, L. et al. Suppression of poly (ADP-ribose) polymerase activation by 3-aminobenzamide in a rat model of myocardial infarction: long-term morphological and functional consequences. Br. J. Pharmacol. 133, 1424-1430 (2001).
88. Szabó, C. et al. Inhibition of poly (ADP-ribose) synthetase attenuates neutrophil recruitment and exerts antiinflammatory effects. J. Exp. Med. 186, 1041-1049 (1997).
89. Szabó, C., Cuzzocrea, S., Zingarelli, B., O'Connor, M. & Salzman, A. L. Endothelial dysfunction in a rat model of endotoxic shock. Importance of the activation of poly (ADP-ribose) synthetase by peroxynitrite. J. Clin. Invest. 100, 723-735 (1997).
90. Szabó, C. et al. Angiotensin II-mediated endothelial dysfunction: role of poly(ADP-ribose) polymerase activation. Mol. Med. 10, 28-35 (2004).
91. Pacher, P., Mabley J. G., Soriano, F. G., Liaudet, L. & Szabó, C. Activation of poly(ADP-ribose) polymerase contributes to the endothelial dysfunction associated with hypertension and aging. Int. J. Mol. Med. 9, 659-664 (2002).
92. Zhang, C., Yang, J. & Jennings, L. K. Attenuation of neointima formation through the inhibition of DNA repair enzyme PARP-1 in balloon-injured rat carotid artery. Am. J. Physiol. Heart. Circ. Physiol. 287, H659-H666 (2004).
93. Benko, R., Pacher, P., Vaslin, A., Kollai, M. & Szabó, C. Restoration of the endothelial function in the aortic rings of apolipoprotein E deficient mice by pharmacological inhibition of the nuclear enzyme poly(ADP-ribose) polymerase. Life Sci. 75, 1255-1261 (2004).
94. Obrosova, I. G. et al. Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes 53, 711-720 (2004).
95. Zheng, L., Szabó, C. & Kern, T. S. Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-κB. Diabetes 53, 2960-2967 (2004).
96. Delaney, C. A. et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin. Cancer Res. 6, 2860-2867 (2000).
97. Tentori, L. et al. Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components. Cancer Chemother. Pharmacol. 47, 361-369 (2001).
98. Tentori, L., Portarena, I., Bonmassar, E. & Graziani, G. Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells. Cell Death Differ. 8, 457-469 (2001).
99. Calabrese, C. R. et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J. Natl. Cancer Inst. 96, 56-67 (2004).
100. Curtin, N. J. et al. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin. Cancer Res. 10, 881-889 (2004).
101. Yung, T. M., Sato, S. & Satoh, M. S. Poly(ADP-ribosyl)ation as a DNA damage-induced post-translational modification regulating poly(ADP-ribose) polymerase-1-topoisomerase I interaction. J. Biol. Chem. 279, 39686-39696 (2004).
102. Malanga, M. & Althaus, F. R. Poly(ADP-ribose) reactivates stalled DNA topoisomerase I and induces DNA strand break resealing. J. Biol. Chem. 279, 5244-5248 (2004).
103. Munoz-Gamez, J. A. et al. PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis. Biochem. J. 386, 119-125 (2005)
104. Pacher, P. et al. Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J. Pharmacol. Exp. Ther. 300, 862-867 (2002).
105. Szenczi, O. et al. Poly(ADP-ribose) polymerase regulates myocardial calcium handling in doxorubicin-induced heart failure. Biochem. Pharmacol. 69, 725-732 (2005).
106. Chalmers, A. J. Poly(ADP-ribose) polymerase-1 and ionizing radiation: sensor, signaller and therapeutic target. Clin. Oncol. (R. Coll. Radiol.) 16, 29-39 (2004).
107. Rudat, V., Kupper, J. H. & Weber, K. J. Trans-dominant inhibition of poly(ADP-ribosyl)ation leads to decreased recovery from ionizing radiation-induced cell killing. Int. J. Radiat. Biol. 73, 325-330 (1998).
108. Schlicker, A., Peschke, P., Burkle, A., Hahn, E. W. & Kim, J. H. 4-amino-1,8-naphthalimide: a novel inhibitor of poly(ADP-ribose) polymerase and radiation sensitizer. Int. J. Radiat. Biol. 75, 91-100 (1999).
109. Veuger, S. J., Curtin, N. J., Richardson, C. J., Smith, G. C. & Durkacz, B. W. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res. 63, 6008-6015 (2003).
110. Brock, W. A. et al. Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase. Cancer Lett. 205, 155-160 (2004).
111. Ruf, A., Mennissier, D. M., De Murcia, G. & Schulz, G. E. Structure of the catalytic fragment of poly(AD-ribose) polymerase from chicken. Proc. Natl Acad. Sci. USA 93, 7481-7485 (1996).
112. + binding to poly (ADP-ribose) polymerase as derived from crystal structures and homology modeling. Biochemistry 37, 3893-3900 (1998).
113. Ruf, A., Rolli, V., De Murcia, G. & Schulz, G. E. The mechanism of the elongation and branching reaction of poly (ADP-ribose) polymerase as derived from crystal structures and mutagenesis. J. Mol. Biol. 278, 57-65 (1998).
114. Nguewa, P. A., Fuertes, M. A., Alonso, C. & Perez, J. M. Pharmacological modulation of poly(ADP-ribose) polymerase-mediated cell death: exploitation in cancer chemotherapy. Mol. Pharmacol. 64, 1007-1014 (2003).
115. Oliver, A. W. et al. Crystal structure of the catalytic fragment of murine poly(ADP-ribose) polymerase-2. Nucleic Acids Res. 32, 456-464 (2004).
116. Kinoshita, T. et al. Inhibitor-induced structural change of the active site of human poly (ADP-ribose) polymerase. FEBS Lett. 556, 43-46 (2004).
117. Hattori, K. et al. Rational approaches to discovery of orally active and brain-penetrable quinazolinone inhibitors of poly(ADP-ribose)polymerase. J. Med. Chem. 47, 4151-4154 (2004).
118. Banasik, M. & Ueda, K. Inhibitors and activators of ADP-ribosylation reactions. Mol. Cell Biochem. 138, 185-197 (1994).
119. Banasik, M., Komura, H., Shimoyama, M. & Ueda, K. Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J. Biol. Chem. 267, 1569-1575 (1992).
120. Li, J. H. & Zhang, J. PARP inhibitors. IDrugs 4, 804-812 (2001).
121. Southan, G. J. & Szabó, C. Poly(ADP-ribose) polymerase inhibitors. Curr. Med. Chem. 10, 321-340 (2003).
122. Peukert, S. & Schwahn, U. New inhibitors of poly(ADP-ribose)polymerase (PARP). Expert Opin. Ther. Patents 14, 1531-1551 (2004).
123. Suto, M. J., Turner, W. R., Arundel-Suto, C. M., Werbel, L. M. & Seboly-Leopold J. S. Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose) polymerase. Anticancer Drug Design 6, 107-117 (1991).
124. Pivaziyan, A. D., Birks, E. M., Wood, T. G., Lin, T. S. and Prusoff, W. H. Inhibition of poly(ADP-ribose) polymerase activity by nucleoside analogs of thymidine. Biochem. Pharmacol. 44, 947 (1992).
125. Steinhagen, H., Gerisch, M., Mittendorf, J., Schlemmer, K. H. & Albrecht, B. Substituted uracil derivatives as potent inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). Bioorg. Med. Chem. Lett. 12, 3187-3190 (2002).
126. Jagtap, P. G. et al. The discovery and synthesis of novel adenosine substituted 2,3-dihydro-1-H-isoindol-1-ones: potent inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1). Bioorg. Med. Chem. Lett. 14, 81-85 (2004).
127. LaPlaca, M. C. et al. Pharmacologic inhibition of poly(ADP-ribose) polymerase is neuroprotective following traumatic brain injury in rats. J. Neurotrauma 18, 369-376 (2001).
128. Mazzon, E. et al. GPI 6150, a poly(ADP-ribose) polymerase inhibitor, exhibits an anti-inflammatory effect in rat models of inflammation. Eur. J. Pharmacol. 415, 85-94 (2001).
129. Mazzon, E. et al. Beneficial effects of GPI 6150, an inhibitor of poly(ADP-ribose) polymerase in a rat model of splanchnic artery occlusion and reperfusion. Shock 17, 222-227 (2002).
130. Mazzon, E. et al. GPI 6150, a PARP inhibitor, reduces the colon injury caused by dinitrobenzene sulfonic acid in the rat. Biochem. Pharmacol. 64, 327-337 (2002).
131. Feng, Y. & LeBlanc M. H. Drug-induced hypothermia begun 5 minutes after injury with a poly(adenosine 5′-diphosphate-ribose) polymerase inhibitor reduces hypoxic brain injury in rat pups. Crit. Care Med. 30, 2420-2424 (2002).
132. Zhang, J. in PARP as a Therapeutic Target (ed. Zhang, J. C.) 239-333 (CRC Press, Boca Raton, Florida, 2002).
133. Jagtap, P. et al. Novel phenanthridinone inhibitors of poly(adenosine 5′-diphosphate-ribose) synthetase: potent cytoprotective and anti-shock agents. Crit. Care Med. 30, 1071-1082 (2002).
134. Abdelkarim, G. E. et al. Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke. Int. J. Mol. Med. 7, 255-260 (2001).
135. Faro, R. et al. Myocardial protection by PJ34, a novel potent poly(ADP-ribose) synthetase inhibitor. Ann. Thorac. Surg. 73, 575-581 (2002).
136. Szabó, G. et al. Poly(ADP-ribose) polymerase inhibition reduces reperfusion injury after heart transplantation. Circ. Res. 90, 100-106 (2002).
137. Goldfarb, R. D. et al. Protective effects of a novel, potent inhibitor of poly(adenosine 5′-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis. Crit. Care Med. 30, 974-980 (2002).
138. Mabley, J. G. et al. Anti-inflammatory effects of a novel, potent inhibitor of poly(ADP-ribose) polymerase. Inflamm. Res. 50, 561-569 (2001).
139. Pacher, P., Liaudet, L., Mabley, J., Komjati, K. & Szabó, C. Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure. J. Am. Coll. Cardiol. 40, 1006-1016 (2002).
140. Pacher P. et al. The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes 51, 514-521 (2002).
141. Pacher P. et al. Endothelial dysfunction in aging animals: the role of poly(ADP-ribose) polymerase activation. Br. J. Pharmacol. 135, 1347-1350 (2002).
142. Iwashita, A. et al. Neuroprotective effects of a novel poly(ADP-ribose) polymerase-1 inhibitor, 2-[3-[4-(4-chlorophenyl)-1-piperazinyl] propyl]-4(3H)-quinazolinone (FR255595), in an in vitro model of cell death and in mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J. Pharmacol. Exp. Ther. 309, 1067-1078 (2004).
143. Iwashita, A. et al. A novel and potent PARP-1 inhibitor, 5-chloro-2-[3-(4-phenyl-3, 6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone (FR247304), attenuates neuronal damage in vitro and in vivo models of cerebral schemia. J. Pharmacol. Exp. Ther. 310, 425-436 (2004).
144. Iwashita, A. et al. A new poly(ADP-ribose) polymerase inhibitor, 2-(4-chlorophenyl)-5-quinoxalinecarboxamide (FR261529), ameliorates methamphetamine-induced dopaminergic neurotoxicity in mice. J. Pharmacol. Exp. Ther. 310, 1114-1124 (2004).
145. Kamanaka, Y. et al. Neuroprotective effects of ONO-1924H, an inhibitor of poly(ADP-ribose) polymerase (PARP), on cytotoxicity of PCI2 cells and ischemic cerebral damage. Life Sci. 76, 151-162 (2004).
146. Pellicciari, R. et al. Towards new neuroprotective agents: design and synthesis of 4H-thieno[2,3-c] isoquinoline-5-one derivatives as potent PARP-1 inhibitors. Farmaco 58, 851-858 (2003).
147. Chiarugi, A. et al. Novel isoquinolinone-derived inhibitors of poly(ADP-ribose) polymerase-1: pharmacological characterization and neuroprotective effects in an in vitro model of cerebral ischemia. J. Pharmacol. Exp. Ther. 305, 943-949 (2003).
148. Nakajima, H., Kakui, N., Ohkuma, K., Ishikawa, M. & Hasegawa, T. A newly synthesized poly(ADP-ribose) polymerase inhibitor. 2-methyl-3,5,7,8-tetrahydrothipyrano[4,3-d]pyrimidine-4-one (DR2313): pharmacological profiles, neuroprotective effects, and therapeutic time window in cerebral ischemia in rats. J. Pharmacol. Exp. Ther. 312, 472-481 (2005).
149. Ferraris, D. et al. Design and synthesis of poly ADP-ribose polymerase-1 inhibitors. 2. Biological evaluation of aza-5[H]-phenanthridin-6-ones as potent, aqueous-soluble compounds for the treatment of ischemic injuries. J. Med. Chem. 46, 3138-3151 (2003).
150. Ferraris, D. et al. Design and synthesis of poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors. Part 3: In vitro evaluation of 1,3,4,5-tetrahydro-benzo[c][1,6]- and [c][1,7]-naphthyridin-6-ones. Bioorg. Med. Chem. Lett. 13, 2513-2518 (2003).
151. White, A. W. et al. Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase. J. Med. Chem. 46, 3138-3151 (2003).
152. Canan-Koch, S. S. et al. Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure. J. Med. Chem. 45, 4961-4974 (2002).
153. Skalitzky, J. D. et al. Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. J. Med. Chem. 46, 210-213 (2003).
154. Calabrese, C. R. et al. Identification of potent nontoxic poly(ADP-ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin. Cancer Res. 9, 2711-2718 (2003).
155. Tikhe, J. G. et al. Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase. J. Med. Chem. 47, 5467-5481 (2004).
156. Curtin, N. PARP-1: A New Target for Cancer Treatment. Cancer Research UK Scientific Yearbook 52-54 (2002-03).
157. Farraris, D. et al. Design and synthesis of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. Part 4: biological evaluation of imidazobenzodiazepines as potent PARP-1 inhibitors for treatment of ischemic injuries. Bioorg. Med. Chem. 11, 3695-3707 (2003).
158. Zimmermann, K., Portmann, R. & Rigel, D. Indoloquinazolinones. US Patent 0199505 A (2003).
159. Miknyoczki, S. J. et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a novel poly(ADP-ribose) polymerase inhibitor. Mol. Cancer Ther. 2, 371-382 (2003).
160. Jagtap, P. G., Baloglu, E., van Duzer, J. H., Szabó, C. & Salzman, A. Substituted indeno[1,2-c]isoquinoline derivatives and methods of use thereof. US Patent 6,828,319 (2004).
161. Komjati, K. et al. Poly(ADP-ribose) polymerase inhibition protect neurons and the white matter and regulates the translocation of apoptosis-inducing factor in stroke. Int. J. Mol. Med. 13, 373-382 (2004).
162. Woolley, S. M. et al. Role of poly(ADP) ribose synthetase in lung ischemia-reperfusion injury. J. Heart Lung Transplant. 23, 1290-1296 (2004).
163. Xiao, C. Y. et al. Poly(ADP-ribose) polymerese promotes cardiac remodeling, contractile failure and translocation of apoptosis-inducing factor in a murine experimental model of aortic banding and heart failure. J. Pharmacol. Exp. Ther. 3/2, 891-898 (2005).
164. Farivar, A. S. et al. Intratracheal poly(ADP) ribose synthetase inhibition ameliorates lung ischemia reperfusion injury. Ann. Thorac. Surg. 77, 1938-1943 (2004).
165. Murthy, K. G., Xiao, C. Y., Mabley, J. G., Chen, M. & Szabó, C. Activation of poly(ADP-ribose) polymerase in circulating leukocytes during myocardial infarction. Shock 21, 230-234 (2004).
166. Li, F., Drel, V. R., Szabó, C., Stevens, M. J. & Obrosova, I. G. Low dose PARP inhibitor-containing combination therapies reverse early experimental diabetic neuropathy. Diabetes (in the press).
167. Iwashita, A. et al. Discovery of quinazoline and quinoxaline derivatives as potent and selective poly(ADP-ribose)polymerase-1/2 inhibitors. FEBS Lett.579, 1389-1393 (2005).
168. Popoff, I. et al. Antisense oligonucleotides to poly(ADP-ribose) polymerase-2 ameliorate colitis in interleukin-10-deficient mice. J. Pharmacol. Exp. Ther. 303, 1145-1154 (2002).
169. Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917 (2005).
170. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005).